Acute dystonia caused by tetrabenazine - What does it tell us about pathophysiology?

European Journal of Neurology

Volumn 3, Issue 4, 1996, Pages 395-396

  Dietrichs, E ^a   Magnusson, A ^a   Opjordsmoen, S ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Dystonia; Extrapyramidal side effects; Tetrabenazine

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; CATECHOLAMINE; CENTRAL MUSCLE RELAXANT; DIAZEPAM; ORPHENADRINE; TETRABENAZINE;

ADULT; ARTICLE; CASE REPORT; CATECHOLAMINE DEPLETION; DOPAMINERGIC TRANSMISSION; DYSTONIA; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUICIDE ATTEMPT;

EID: 0029778962     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1996.tb00236.x     Document Type: Article

References (20)

1. Asher SW and Aminoff MJ (1981) Tetrabenazine and movement disorders. Neurology, 31, 1051-1054.
2. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K and Willner JH (1981) Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology, 31, 1022-1026.
3. Burke RE, Reches A, Traub MM, Ilson J, Swash M and Fahn S (1985). Tetrabenazine induces acute dystonic reactions. Annals of Neurology, 17, 200-202.
4. Carlsson A (1978) Mechanism of action of neuroleptic drugs. In: Psychopharmacology: a Generation of Progress (Eds MA Lipton, A DiMascio and KF Killam), pp. 1057-1070. New York, Raven Press.
5. Erickson JD and Eiden LE (1993) Functional identification and molecular cloning of a human brain vesicle monoamine transporter. Journal of Neurochemistry, 61, 2314-2317.
6. Fahn S (1989) Adverse effects of levodopa in Parkinson's disease. In: Drugs for the Treatment of Parkinson's Disease (Ed. DB Calne), pp. 385-409. Berlin, Springer.
7. Fahn S (1995) Medical treatment of dystonia. In: Handbook of Dystonia (Eds JKC Tsui and DB Calne), pp. 317-328. New York, Marcel Dekker.
8. Garver DL, Davis DM, Dekirmenjian H, Ericksen S, Gosenfeld L and Haraszti J (1976) Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacologia, 47, 199-201.
9. Kolbe H, Clow A, Jenner P and Marsden CD (1981) Neuroleptic-induced acute dystonic reaction may be due to enhanced dopamine release on supersensitive postsynaptic receptors. Neurology, 31, 434-439.
10. Lane JD, Smith JE, Shea PA and McBride WJ (1976) Neurochemical changes following the administration of depleters of biogenic monoamine. Life Science, 19, 1663-1667.
11. LeWitt PA (1995) Dystonia caused by drugs. In: Handbook of Dystonia (Eds JKC Tsui and DB Calne), pp. 227-240. New York, Marcel Dekker.
12. Liebman JM (1986) Tetrabenazine and dystonia in primates. Annals of Neurology, 19, 203-204.
13. Login IS, Cronin MJ and MacLeod RM (1982) Tetrabenazine has properties of a dopamine receptor antagonist. Annals of Neurology, 12, 257-262.
14. Mateo D, Muñoz-Blanco JL and Giménez-Roldán (1992) Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clinical Neuropharmacology, 15, 63-68.
15. McCann UD, Penetar DM and Belensky G (1990) Acute dystonic reaction in normal humans caused by catecholamine depletion. Clinical Neuropharmacology, 13, 565-568.
16. Neale R, Gerhardt S and Liebman JM (1984) Effects of dopamine agonists, catecholamine depletors and cholinergic and GABA-ergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology, 82, 20-26.
17. Pakkenberg H (1968) The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurologica Scandinavica, 44, 391-393.
18. Reches A, Burke RE, Kuhn C, Hassan MN, Jackson VR and Fahn S (1983) Tetrabenazine, an amine depleting agent, also blocks dopamine receptors in rat brain. Journal of Pharmacology Experiment and Theory, 225, 515-521.
19. Rupniak NM, Jenner P and Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology, 88, 403-419.
20. Schott K, Ried S, Stevens I and Dichgans J (1989) Neuroleptically induced dystonia in Huntington's disease: a case report. European Journal of Neurology, 29, 39-40.